Research programme: droxidopa controlled-release - Lundbeck

Drug Profile

Research programme: droxidopa controlled-release - Lundbeck

Alternative Names: CR droxidopa; Northera™ controlled release; Threo-DOPS controlled release

Latest Information Update: 01 Jul 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chelsea Therapeutics
  • Developer Lundbeck A/S
  • Class Amino acids; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypotension

Most Recent Events

  • 01 Jul 2014 Discontinued - Preclinical for Hypotension in USA (PO, controlled-release)
  • 24 Jun 2014 Chelsea Therapeutics has been acquired by Lundbeck A/S
  • 16 Dec 2011 Preclinical trials in Hypotension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top